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                                Phase I trials represent the first application of a new drug or drug 
combination to humans and as such are the foundation of a success-
ful clinical drug development process. Because the early clinical 
development of a novel agent may unduly influence its ultimate fate, 
a careful and thoughtful approach to the design of phase I trials is 
essential. Phase I clinical trials in oncology are typically small, sin-
gle-arm, open-label, sequential studies that include patients with a 
good performance status whose cancers have progressed despite 
standard treatments. A principal goal of such trials is to establish the 
recommended dose and/or schedule of an experimental drug or 
drug combination for efficacy testing in phase II trials. A phase I trial 
design has many components, including starting dose, dose incre-
ment, dose escalation method, number of patients per dose level, 
specification of dose-limiting toxicity, target toxicity level, definition 
of the maximum tolerated dose (MTD) and recommended dose for 
phase II trials, patient selection, and number of participating centers 
(  see   definitions of basic concepts in   Table 1  ). Although all of these 
components are relevant for the design of a phase I trial, this review 
will focus on selecting the dose escalation method that will yield an 
optimal balance of safety, efficiency, and ethical conduct.         
  The guiding principle for dose escalation in phase I trials is to 
avoid unnecessary exposure of patients to subtherapeutic doses of 
an agent (ie, to treat as many patients as possible within the thera-
peutic dose range) while preserving safety and maintaining rapid 
accrual. Dose escalation methods for phase I cancer clinical trials 
fall into two broad classes: the rule-based designs, which include 
the traditional 3+3 design and its variations, and the model-based 
designs. The rule-based designs assign patients to dose levels 
according to prespeciﬁ  ed rules based on actual observations of 
target events (eg, the dose-limiting toxicity) from the clinical data. 
Typically, the MTD or recommended dose for phase II trials is 
determined by the prespeciﬁ  ed rules as well. On the other hand, 
the model-based designs assign patients to dose levels and deﬁ  ne 
the recommended dose for phase II trials based on the estimation 
of the target toxicity level by a model depicting the dose  –  toxicity 
relationship. However, because of safety concerns, most model-
based designs are modiﬁ  ed such that speciﬁ  c restrictions are set as 
safeguards for elements such as dose increments to avoid over-
shooting of the MTD and thus exposing patients to undue harm. 
All of these methods were developed in the era of cytotoxic drugs, 
during which time it was assumed that both efﬁ  cacy and toxicity 
increase with dose. These relationships are typically represented 
by dose  –  toxicity and dose  –  efﬁ  cacy curves in which toxicity and 
efﬁ  cacy increase monotonically with increasing dose (  Table 1   and 
  Figure 1  ). Consequently, these methods have used toxicity as the 
primary endpoint. For molecularly targeted agents, the dose  – 
efﬁ  cacy and dose  –  toxicity curves may differ from those for cyto-
toxic agents, and efﬁ  cacy may occur at doses that do not induce 
clinically signiﬁ  cant toxicity (  1    –    4  ). Thus, for trials involving these 
agents, the occurrence of drug-related biological effects has been 
suggested as an alternate primary endpoint besides toxicity (  1    –    4  ).         
  Here we review the different dose escalation methods for phase I 
cancer clinical trials of single agents and drug combinations and 
discuss their pros and cons. Recent reviews (  2  ,  5  ) of phase I clinical 
trials including this update reveal that new dose escalation designs 
have been incorporated into phase I trials infrequently, and we 
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explore the reasons for this disconnect. Finally, we recommend 
ways to assign dose escalation methods to evaluate new drugs or 
drug combinations. These recommendations are based on pre-
clinical information, existing knowledge of agents that target the 
same or similar molecular pathways, and the availability of 
resources to execute such methods. 
    Rule-Based Designs 
  The main characteristic of rule-based designs is that they do 
not stipulate any prior assumption of the dose  –  toxicity curve. 
These designs comprise the so-called “up-and-down” designs 
because they allow dose escalation and de-escalation. The first up-
and-down design was introduced in the late 1940s by Dixon and 
Mood (  6  ), and Storer (  7  ) described implementation of this design 
in clinical practice half a century later. The general principle of 
this design is to escalate or de-escalate the dose with diminishing 
fractions of the preceding dose depending on the absence or 
  presence of severe toxicity in the previous cohort of treated 
patients (  Figure 2, A  ). The simple up-and-down design converges 
to a dose that corresponds to a probability of severe toxicity of 
approximately 50%, which is higher than the 33% threshold com-
monly accepted in most phase I cancer clinical trials. Although 
variations of this up-and-down design have been developed in an 
attempt to increase patient safety and to use toxicity data collected 
in real time (  8  ,  9  ), these designs have not been used much in clinical 
practice because they risk exposing patients to unacceptable levels 
of toxicity. The first rule-based design to be used widely in clinical 
practice was the traditional 3+3 design. Variations of the tradi-
tional 3+3 design that have been put into clinical use include the 
accelerated titration designs and the pharmacologically guided 
dose escalation (PGDE) method.         
    Traditional 3+3 Design 
  The traditional 3+3 design remains the prevailing method for con-
ducting phase I cancer clinical trials (  7  ). It requires no modeling of 
  Table 1    .       Glossary of terms   
    Term Definition   
    Cohort Group of patients treated at a dose level. 
  Starting dose The dose chosen to treat the first cohort of patients in a phase I trial. 
  Dose increment (decrement) The percent increase (or decrease) between dose levels. 
  Dose-limiting toxicity (DLT) Toxic effects that are presumably related to the drugs that are considered unacceptable (because 
  of their severity and/or irreversibility) and that limit further dose escalation. DLTs are defined before 
  beginning the trial and are protocol specific. They are typically defined based on toxic effects seen in 
  the first cycle and specified using a standardized grading criteria, for example, Common Terminology 
  Criteria for Adverse Events. 
  Dose  –  efficacy curve The dose  –  efficacy curve reflects the relationship between dose and probability of efficacy for an 
  anticancer agent. A logistic function is commonly assumed to describe the dose  –  efficacy curve for 
  cytotoxic agents and is characterized by a parameter,     , which represents the slope of the 
 dose  –  efficacy curve. Small values of      indicate that the probability of efficacy increases very slowly 
  with increasing dose levels, whereas large values of      indicate a sharp increase in efficacy with 
  increasing dose levels (  see     Figure 1  ). 
  Dose  –  toxicity curve The dose  –  toxicity curve reflects the relationship between dose and probability of toxicity for an 
  anticancer agent. A logistic function is commonly assumed to describe the dose  –  toxicity curve for 
  cytotoxic agents and is characterized by a parameter,     , which represents the slope of the 
 dose  –  toxicity curve. Small values of      indicate that the probability of toxicity increases very slowly 
  with increasing dose levels, whereas large values of      indicate a sharp increase in toxicity with 
  increasing dose levels (  see     Figure 1  ). 
  Target toxicity level The maximum probability of DLT that is considered acceptable in the trial. The target toxicity level in 
  phase I trials is typically between 20% and 33%. 
  Maximum tolerated dose (MTD) Phase I trials conducted in the United States: the highest dose level at which   ≤  33% of patients 
 experience  DLT. 
  Phase I trials conducted in Europe and Japan: the lowest dose level at which   ≥  33% of patients 
  experience DLT (a misnomer in the sense that the MTD is actually not a tolerable dose). 
  Phase I trials that use model-based methods: the dose that produces the target toxicity level. 
  Optimal biological dose (OBD) Dose associated with a prespecified most desirable effect on a biomarker among all doses studied 
  (eg, inhibition of a key target in tumor or surrogate tissue or achievement of a prespecified 
 immunologic  parameter). 
  Recommended phase II dose Phase I trials with a toxicity endpoint that are conducted in the United States: the MTD. 
  Phase I trials with a toxicity endpoint that are conducted in Europe and Japan: one dose level below 
 the  MTD. 
  Phase I trials in which the endpoint is a prespecified biological endpoint: the OBD. 
  Pharmacokinetics Pharmacologic effects of the body on the drug (ie, the time course of drug absorption, distribution, 
  metabolism, and excretion). 
  Pharmacodynamics Pharmacologic effects of the drug on the body (eg, nadir neutrophil or platelet count, nonhematologic 
  toxicity, molecular correlates, imaging endpoints). 
  Therapeutic index The dosage or range of dosages of a drug that is required to produce a given level of damage to critical 
  normal tissues (toxicity) divided by the dosage or range of dosages that yields a defined level of 
  antitumor effect (efficacy) (  see     Figure 1  ).   710   Review | JNCI  Vol. 101, Issue 10  |  May 20, 2009
the dose  –  toxicity curve beyond the classical assumption for cyto-
toxic drugs that toxicity increases with dose. This rule-based 
design proceeds with cohorts of three patients; the first cohort is 
treated at a starting dose that is considered to be safe based on 
extrapolation from animal toxicological data, and the subsequent 
cohorts are treated at increasing dose levels that have been fixed in 
advance (  Figure 2, B  ). Historically, dose escalation has followed a 
modified Fibonacci sequence in which the dose increments become 
smaller as the dose increases (eg, the dose first increases by 100% 
of the preceding dose, and thereafter by 67%, 50%, 40%, and 
30%  –  35% of the preceding doses). In most cases, the prespecified 
dose levels do not fit the exact Fibonacci sequence as described in 
the 12th century (  5  ). If none of the three patients in a cohort expe-
riences a dose-limiting toxicity, another three patients will be 
treated at the next higher dose level. However, if one of the first 
three patients experiences a dose-limiting toxicity, three more 
patients will be treated at the same dose level. The dose escalation 
continues until at least two patients among a cohort of three to six 
patients experience dose-limiting toxicities (ie,   ≥  33% of patients 
with a dose-limiting toxicity at that dose level). The recommended 
dose for phase II trials is conventionally defined as the dose level 
just below this toxic dose level. 
  Alternative rules besides “3+3” have been proposed, including 
the “2+4,” “3+3+3,” and “3+1+1” (also referred as “best of ﬁ  ve”) 
rules (  10  ). In the “2+4” design, an additional cohort of four patients 
is added if one dose-limiting toxicity is observed in a ﬁ  rst cohort of 
two patients. The stopping rule is the same as in the traditional 3+3 
design. In the “3+3+3” design, a third cohort of three patients is 
added if two of six patients in the ﬁ  rst two cohorts experience a 
dose-limiting toxicity at a certain dose level. The trial terminates if 
at least three of nine patients experience a dose-limiting toxicity. 
The “best of ﬁ  ve” design is more aggressive than the traditional 
3+3 design in that one additional patient is added if one or even 
two dose-limiting toxicities are observed among the ﬁ  rst three 
patients. Another patient is added if two dose-limiting toxicities 
are observed among the four treated patients. Dose escalation is 
allowed if dose-limiting toxicities are observed among none of 
three, one of four, or two of ﬁ  ve patients, but the trial will termi-
nate if three or more dose-limiting toxicities are observed. 
  The main advantages of the traditional 3+3 design are that it is 
simple to implement and safe (  Table 2  ). In addition, the accrual of 
three patients per dose level provides additional information about 
pharmacokinetic interpatient variability. However, a disadvantage 
of this design is that it involves an excessive number of escalation 
steps, which results in a large proportion of patients who are 
treated at low (ie, potentially subtherapeutic) doses while few 
patients actually receive doses at or near the recommended dose 
for phase II trials. This latter point is illustrated in   Table 3  , which 
presents the dose escalation method used as well as the number of 
dose levels in recent ﬁ  rst-in-human single-agent phase I trials for 
anticancer agents that were eventually (1992  –  2008) approved by 
the US Food and Drug Administration (FDA) for the treatment of 
solid tumors. Among 21 trials that used the traditional 3+3 design, 
more than half involved six or more dose levels.                   
    Accelerated Titration Designs 
  Accelerated titration designs combine features from variations of 
the traditional 3+3 design and the model-based design. Because the 
patient assignment to doses is based on prespecified rules, we clas-
sify accelerated titration designs       as rule-based designs. Through 
simulations based on a stochastic model fit to data from 20 actual 
phase I trials of nine different drugs, Simon et al. (  36  ) described 
one control design and three accelerated titration designs. The 
control design, design 1, is a standard 3+3 design with a 40% dose 
increment between successive cohorts of patients. Although the 
three accelerated titration designs, designs 2, 3, and 4, were created 
based on a statistical model as described (  36  ), the assignment of 
patients to dose levels follows specific rules according to the 
observed toxicities at each dose level. Designs 2 and 3 allow 40% 
and 100% dose escalations, respectively, between single-patient 
cohorts until a dose-limiting toxicity or two moderate toxicities are 
observed during cycle 1, at which point dose escalation reverts to 
the more conservative one used in design 1. In design 4, the 100% 
dose escalation between single-patient cohorts in the accelerated 
phase reverts to design 1 when one dose-limiting toxicity or two 
moderate toxicities are observed during any cycle (not just during 
cycle 1). Intrapatient dose escalation is allowed during the acceler-
ated phase of designs 2, 3, and 4 (  Figure 2, C  ). In all three acceler-
ated titration designs, the standard 3+3 design is used after the 
accelerated phase as a stopping rule, and then the described model 
is recommended to estimate the MTD with all toxicity data col-
lected during the trial. In addition, the model recommended for 
use included a parameter for cumulative toxicity as well as a para-
meter for interpatient variability, such that the accelerated titra-
tion designs would provide information in these aspects. In 
practice, investigators often determine the MTD based on the 
conventional 3+3 escalation rule without fitting trial data to the 
model at the end of the trial. Consequently, the original model-
based accelerated titration designs have been adapted primarily as 
rule-based designs in clinical practice. 
  The accelerated phase in accelerated titration designs  —  in 
which only one patient is included per dose level  —  along with the 
possibility of intrapatient dose escalation theoretically reduce the 
number of patients who are treated at subtherapeutic doses 
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    Figure 1    .       Typical dose  –  toxicity and dose  –  efﬁ  cacy curves for cytotoxic 
agents. This example illustrates that at dose   x  , the probability of efﬁ  -
cacy is 30% and the probability of toxicity is 10%; hence, the therapeutic 
index of the drug at dose   x   is 10% divided by 30% = 1/3.         jnci.oxfordjournals.org    JNCI | Review 711
(  Table 2  ). Permitting intrapatient dose escalation in accelerated 
titration designs is appealing because it gives some patients the 
opportunity to be treated at higher and presumably more effective 
doses. For example, in the ﬁ  rst-in-human phase I trial of ixabepi-
lone, which used an accelerated titration design with intrapatient 
dose escalation, all patients received the drug at the eventually 
established recommended dose for phase II trials (  35  ). On the 
other hand, unless the model recommended in the original publi-
cation (36)       using parameters for cumulative toxicity and interpa-
tient variability is applied and ﬁ  ts the data well, one drawback of 
intrapatient dose escalation is that it may mask the cumulative 
effects of treatment or, at the very least, would make them harder 
to differentiate from chronic or delayed toxic effects. However, 
regardless of the trial design used, chronic, delayed, or cumulative 
toxic effects are generally not well captured by most phase I trials 
because most patients with advanced cancers do not remain on 
study for extended periods of time. Furthermore, it can be difﬁ  cult 
to present and interpret results of trials that allow intrapatient dose 
escalations because a single patient may contribute data for several 
dose levels.   
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  Figure 2    .       Graphical depiction of dose escalation methods for phase I 
cancer clinical trials. Each   box   represents a cohort comprising the indi-
cated number of patients treated at a given dose level.   A  ) Simple 
up-and-down design.   B  ) Traditional 3+3 design.   C  ) Accelerated titra-
tion design.   Dashed arrows   represent intrapatient dose escalation. 
  D  ) Pharmacologically guided dose escalation.   E  ) Modiﬁ  ed  continual 
reassessment method.  F  ) Escalation with overdose control. “Overdosing 
or excessive overdosing” refers to doses that exceed the MTD. DLT = 
dose-limiting toxicity; SD = starting dose; RD = recommended dose; DL 
= dose level; AUC = area under the curve for drug concentration as a 
function of time; p(DLT at next DL) = probability of dose-limiting toxicity 
at the next dose level.       712   Review | JNCI  Vol. 101, Issue 10  |  May 20, 2009
    Pharmacologically Guided Dose Escalation 
  The PGDE method is another variation of the traditional 3+3 
design that has not been widely used in clinical practice. This 
approach assumes that dose-limiting toxicities can be predicted 
by plasma drug concentrations and that animal models can 
accurately reflect this relationship in humans (  37  ). The PGDE 
method has two stages. A prespecified plasma exposure defined 
by the area under the curve for drug concentration as a function 
of time (AUC) is extrapolated from preclinical data. Then, 
pharmacokinetic data are obtained for each patient in real time 
to determine the subsequent dose level. As long as the prespeci-
fied plasma exposure is not reached, dose escalation proceeds 
with one patient per dose level and typically at 100% dose 
increments (stage 1,   Figure 2, D  ). When the target AUC is 
reached or if dose-limiting toxicities occur, dose escalation 
switches to the traditional 3+3 design with smaller (usually 
around 40%) dose increments (stage 2). 
  The PGDE method has not been widely adopted due to prac-
tical obstacles, including: 1) logistic difﬁ  culties in obtaining real-
time pharmacokinetic results, which are required to determine 
the safety of the subsequent dose escalation; 2) problems in 
extrapolating preclinical pharmacokinetic data to phase I studies 
with different treatment schedules; and 3) risk of exposing the 
next patient to a highly toxic dose if the AUC obtained in the 
preceding patient was atypically low due to interpatient variabil-
ity in drug metabolism. In clinical practice, the PGDE method 
has reliably deﬁ  ned the recommended dose for phase II trials for 
some cytotoxic agents such as certain anthracyclines and   platinum 
compounds but has been found to be inappropriate for other 
classes of cytotoxic agents such as the antifolates, which display a 
high interpatient pharmacokinetic heterogeneity (  38  ).  
    Other Rule-Based Designs 
  Several other rule-based designs have been proposed, including 
the isotonic regression model (  39  ), the biased coin design (  9  ) 
and its variations (  40  ,  41  ), and the “rolling six” design (  42  ). The 
rolling six design was originally proposed as a way to shorten 
the timeline of pediatric phase I trials by reducing the number 
of times a study is suspended to accrual (  42  ). This method 
allows accrual of two to six patients concurrently onto a dose 
level based on the numbers of patients who are currently 
enrolled and evaluable, who experience a dose-limiting toxicity 
and who remain at risk of developing a dose-limiting toxicity. 
Because pediatric trials are typically conducted only after com-
pletion of adult phase I trials, this design is intended to shorten 
the study duration in situations in which there is prior informa-
tion about the dose range to be evaluated. 
  Ji et al. (  43  ) developed a rule-based design in which subse-
quent patients are assigned to doses according to the toxicity 
outcome at the current dose by calculating the toxicity probabil-
ity interval under the beta-binomial model. The authors also 
developed a freely available macro in Microsoft Ofﬁ  ce  Excel 
software that can be downloaded to facilitate the study conduct. 
Simulations have shown that the performance of this dose- 
ﬁ  nding design is better than the traditional 3+3 design and com-
parable to some model-based designs.   
  Table 2    .       Theoretical main advantages and drawbacks of dose escalation methods for phase I cancer clinical trials  *     
    Dose escalation method Advantages Drawbacks   
    Rule-based designs   
         Traditional 3+3 design Easy to implement and safe Many patients treated at subtherapeutic doses 
  Slow dose escalation 
  Provide some data on PK interpatient variability Uncertainty about the RP2D 
  Only the result from the current dose is used 
  for determining the dose of next cohort of 
  patients. Information on other doses is ignored. 
         Accelerated titration designs More rapid dose escalation If model fitting is not performed (as is often the 
  case in clinical practice): 
  May expose a greater proportion of patients at 
 higher  doses
       Intrapatient dose escalation may mask 
    cumulative or delayed toxicities 
  Data from all patients, cumulative toxicity, and 
  interpatient variability can be fit to a model to 
  establish the RP2D
       Difficult interpretation of the results when 
    intrapatient dose escalation is allowed 
         Uncertainty about the RP2D 
         Pharmacologically guided dose 
  escalation
More rapid dose escalation Need to obtain real-time PK results 
  Provide some data on PK interpatient variability Interpatient variability may hamper dose 
 escalation 
  Model-based designs    
         Modified continual reassessment 
    method, escalation with overdose 
  control,  time-to-event  continual 
  reassessment  method,  EffTox, 
  TriCRM
Target toxicity level is explicitly defined Need to have a prior guess of the RP2D 
  More rapid dose escalation 
  Use all available information from all patients Computations after each patient or cohort of 
 patients    Estimate of the RP2D with a confidence interval 
  Take into account late-onset toxicities (time-to-event 
  continual reassessment method)
Need real-time biostatistical support for dose 
  escalation decisions (may also be an advantage) 
  Take into account both toxicity and efficacy 
  (EffTox + TriCRM)   
    *     PK = pharmacokinetic; RP2D = recommended phase II dose; EffTox = efficacy and toxicity method; TriCRM = an adaptative continual reassessment method that 
considers three potential trial outcomes: no efficacy and no toxicity, efficacy only, and toxicity only      .     jnci.oxfordjournals.org    JNCI | Review 713
    Summary of Rule-Based Designs 
  The main advantages of rule-based methods are that they are 
easy to implement and do not require special software. However, 
their performance (operating characteristics) is not guaranteed and 
they have some drawbacks. For example, these designs may be 
inefficient in establishing the dose that meets a specific target tox-
icity level. In addition, the decision of dose allocation for future 
patients as well as the definition of the recommended dose for 
phase II trials rely on information from the current dose level and 
do not use all available information. As such, the recommended 
dose for phase II trials is then selected from the prespecified dose 
levels depending on which one best fits the definition of acceptable 
toxicity set a priori. However, although not ideal, the rule-based 
methods have been successful in establishing safe recommended 
doses for phase II trials during the past several decades for antican-
cer agents that were eventually used worldwide in clinical practice 
(  Table 3  ).     
    Model-Based Designs 
  An alternative dose escalation method for phase I clinical trials is 
to use statistical models that actively seek a dose level that pro-
duces a prespecified probability of dose-limiting toxicity by using 
toxicity data from all enrolled patients to compute a more precise 
dose  –  toxicity curve. This method can be conveniently carried 
out  using Bayesian models. Bayesian models require an initial 
  estimation of      (also called prior distribution of     ;   Table 1  ), which 
characterizes the shape of the dose  –  toxicity curve. The occurrence 
of toxicity (or not) in patients enrolled at each dose level provides 
additional information for the statistical model and results in an 
adjustment of      (also called posterior distribution of     ) according 
to Bayes  ’   theorem. The posterior distribution is then evaluated to 
identify the dose closest to the target toxicity level, and this dose is 
used to treat future patients and to set the recommended dose for 
phase II trials. These model-based designs use all of the available 
data to model the dose  –  toxicity curve, and they provide a confi-
dence interval for the recommended dose for phase II trials at the 
end of the trial. 
    Continual Reassessment Method and Modifications 
  The continual reassessment method was the first Bayesian model  –
  based method proposed for adoption in phase I trial designs (  44  ). 
The initial estimate of      required for this method is generally elic-
ited from experts who are familiar with the preclinical data or who 
have experience with similar drugs if any exist. Although this initial 
estimate may not be accurate, it provides guidance about dose 
escalation. In the original description of the continual reassess-
ment method (  44  ), all patients are treated at the dose thought to be 
closest to the MTD, which corresponds to the dose at the target 
dose-limiting toxicity level. The estimation of the probability of 
encountering a dose-limiting toxicity is updated for each new 
patient who enters the study at any dose level until a prespecified 
  Table 3    .       Characteristics of first-in-human phase I clinical trials for recent anticancer agents that were eventually approved by the 
US FDA*   
    Agent
Class or mechanism 
of action
Year of FDA 
approval
Dose escalation 
method
Reason for 
stopping trial
No. of 
patients
No. of 
dose levels Reference   
    Molecular targeted agents             
         Trastuzumab Mab 1998 Traditional PK 18 4 (11) 
         Imatinib TKI 2001 Traditional PK 83 14 (12) 
         Gefitinib TKI 2003 Traditional Toxicity 64 8 (13) 
         Erlotinib TKI 2004 Traditional Toxicity 40 5 (14) 
         Cetuximab Mab 2004 Traditional PK 52 6 (15) 
         Bevacizumab Mab 2004 Traditional Target inhibition 25 5 (16) 
         Sorafenib TKI 2005 Traditional Toxicity 69 >5 (17) 
         Sunitinib TKI 2006 Traditional Toxicity 28 6 (18) 
         Panitumumab Mab 2006 Traditional PK 96 13 (19) 
         Lapatinib TKI 2007 NR NR 81 NR (20) 
         Temsirolimus STKI 2007 Modified CRM Toxicity 24 10 (21) 
  Cytotoxic agents             
         Paclitaxel Anti-tubulin 1992 Traditional Toxicity 34 11 (22) 
         Vinorelbine Alkaloid agent 1994 Traditional + IPDE Toxicity 20 7 (23) 
         Docetaxel Anti-tubulin 1996 ATD Toxicity 39 6 (24) 
         Gemcitabine Antimetabolite 1996 Traditional + IPDE Toxicity 47 12 (25) 
         Topotecan Anti  –  topoisomerase I 1996 Traditional Toxicity 28 5 (26) 
         Irinotecan Anti  –  topoisomerase I 1998 Traditional Toxicity 17 4 (27) 
         Capecitabine Antimetabolite 1998 Traditional Toxicity 34 5 (28) 
         Liposomal doxorubicin Anti  –  topoisomerase II 1999 Traditional Toxicity 26 4 (29) 
         Temozolomide DNA alkylating 1999 Traditional + IPDE Toxicity 51 15 (30) 
         Oxaliplatin DNA alkylating 2002 Traditional + IPDE Toxicity 23 9 (31) 
         Pemetrexed Antimetabolite 2004 Traditional Toxicity 38 10 (32) 
         Trabectedin Alkaloid agent 2004 Traditional Toxicity 21 4 (33) 
         Albumin-bound paclitaxel Anti-tubulin 2005 Traditional Toxicity 19 4 (34) 
         Ixabepilone Anti-tubulin 2007 ATD Toxicity 21 4 (35)   
    *     FDA = US Food and Drug Administration; Mab = monoclonal antibody; TKI = tyrosine kinase inhibitor; STKI = serine/threonine kinase inhibitor; NR = not reported; 
PK = pharmacokinetic data; CRM = continual reassessment method; IPDE = intrapatient dose escalation; ATD = accelerated titration design.     714   Review | JNCI  Vol. 101, Issue 10  |  May 20, 2009
condition is met, at which point the trial is stopped. Various stop-
ping rules have been proposed, the simplest one requires that the 
trial be stopped when six patients are assigned to the same dose 
(  45  ). Alternatively, the trial can be stopped if a certain precision in 
the probability of dose-limiting toxicity at the estimated MTD 
level is achieved. The original continual reassessment method 
allowed for multiple dose escalations and de-escalations. 
  The continual reassessment method as originally described (  44  ) 
has not been well accepted because it can expose patients to unac-
ceptably high (ie, toxic) doses if the prespeciﬁ  ed model is incorrect. 
Consequently, several investigators have recommended modiﬁ  ca-
tions to the continual reassessment method, including: 1) treating the 
ﬁ  rst patient at the lowest starting dose level, which is selected on the 
basis of animal toxicology and conventional criteria (  45  ); 2) increas-
ing the dose by only one prespeciﬁ  ed level at a time (  46    –    48  ); 3) not 
allowing dose escalation for the immediate next patient if a previous 
patient experienced a dose-limiting toxicity (thus hampering multiple 
dose escalations and de-escalations) (  49  ); 4) treating several patients 
at the same dose level, especially for the higher dose levels (  45  ,  47  ,  50  ); 
and 5) expanding the cohort of patients treated at the recommended 
dose for phase II trials (  49  ,  51  ). These modiﬁ  cations have been imple-
mented in clinical practice, resulting in designs similar to the rule-
based designs. For example, the trials start at the lowest dose level 
derived from animal data, a set of dose levels is prespeciﬁ  ed, and up 
to three patients are included per dose level. After each cohort of 
patients completes the ﬁ  rst treatment cycle (or whatever duration of 
time is speciﬁ  ed for the evaluation of dose-limiting toxicity), a com-
putation determines the next dose level that will be tested. A maxi-
mum dose increase for the next dose level is usually prespeciﬁ  ed to 
prevent overdosing, regardless of the recommendation of the model 
(  Figure 2, E  ). In some cases, the model may recommend a dose re-
escalation after a dose de-escalation on the basis of the accumulated 
data on toxicity. A modiﬁ  ed continual reassessment method was used 
in the ﬁ  rst-in-human phase I trial of SAM486A, a polyamine biosyn-
thesis inhibitor (  52  ). The model was successful in that it allowed 
treatment of a single patient per dose level for six of the seven dose 
levels below the recommended dose for phase II trials.   
    Escalation With Overdose Control 
  Some investigators have claimed that the modified continual reas-
sessment method can lead to exposure of patients to high toxic 
doses (  53  ,  54  ). To overcome this limitation, Babb et al. (  53  ) and 
Rogatko et al. (  54  ) suggested an alternative Bayesian approach 
called escalation with overdose control (EWOC). The EWOC 
method is essentially a modified continual reassessment method 
with additional safety measures put in place to avoid exposing 
patients to doses that are potentially too toxic. The only difference 
between the EWOC and the modified continual reassessment 
methods is that with the EWOC method, the probability of 
administering a dose that exceeds the MTD for each higher dose 
level is assessed after each patient, with an interdiction of dose 
escalation if this probability exceeds some critical prespecified 
value (  Figure 2, F  ). For example, the EWOC method would 
restrict the dose escalation if the probabilities of overdosing and 
excessive overdosing exceed specified values (eg, 25% and 5%, 
respectively). Chu et al. (  55  ) have shown that the continual reas-
sessment method and the EWOC method can be unified in a 
hybrid model that seems to be able to determine the target dose 
more expeditiously than the EWOC method and results in smaller 
overdose proportions than the continual reassessment method.   
    Model-Based Designs That Use Time-to-Event Endpoints 
  Because most dose-limiting toxicities are acute events that occur 
soon after delivery of study drugs, phase I trials report dose- 
limiting toxicities that occur during the first one or two treatment 
cycles, generally over a period of a few weeks. However, if an agent 
causes late-onset or cumulative toxicities, an undesirably large 
number of patients may be treated at toxic doses before any toxic-
ity is observed. It is impractical to mandate that phase I trial 
designs have an extended assessment period to monitor for late or 
cumulative toxicity, as this would result in prolonged delays 
between cohort openings and closures. To avoid this limitation, 
several model-based designs have been proposed that use time-to-
event endpoints and do not mandate trial suspension while patients 
are being observed. Cheung and Chappell (  56  ) developed a modi-
fication of the continual reassessment method known as the time-
to-event continual reassessment method (TITE-CRM) that 
incorporates the time to the event (the event being toxicity) for 
each patient. Simulations suggest that for treatments with late-
onset toxicity, the TITE-CRM is more efficient than the tradi-
tional 3+3 design or the continual reassessment method for 
determining the MTD and leads to shorter trial durations (  57  ). 
However, in two clinical trials (  58  ,  59  ), this design led to the 
accrual of more patients to dose levels below the recommended 
dose for phase II trials than would have occurred with the tradi-
tional 3+3 design. A variation of the TITE-CRM has been 
proposed in which accrual is temporarily suspended if the risk of 
toxicity at proposed doses for future patients is unacceptably high 
(  60  ). Although simulations suggest that this variation is safer than 
the originally proposed TITE-CRM design, on average, it tends to 
take a longer time to complete. In addition, designs that use time-
to-event endpoints assume that the hazard of toxicity remains 
constant over time, which may not be the case.   
    Designs That Use Toxicity and Efficacy as Endpoints 
  Efficacy has not traditionally been the primary endpoint for phase I 
trials. However, some situations are particularly relevant for assessing 
both toxicity and efficacy, such as disease-specific phase I trials that 
are designed to examine the sensitivity of one or several tumor types 
to a drug or drug combination. Bayesian-based methods that incor-
porate both toxicity and efficacy in their designs have been developed 
under the assumption that efficacy can be accurately assessed with 
standard response criteria or with surrogate endpoints (  61    –    63  ). For 
example, Thall and Cook (  61  ) proposed the efficacy and toxicity 
method, which defines an acceptable dose combination based on 
trade-offs between the probabilities of treatment efficacy and toxicity. 
Zhang et al. ( 62  ) proposed an adaptive continual reassessment method 
called TriCRM that considers three potential trial outcomes: no effi-
cacy and no toxicity, efficacy only, and toxicity only. Although these 
methods are appealing, they have not yet been widely adopted.   
    Summary of Model-Based Designs 
  Simulations have shown that model-based methods, which use all 
toxicity information accumulated during the trial, achieve good jnci.oxfordjournals.org    JNCI | Review 715
estimations of the target probability of dose-limiting toxicity at the 
recommended dose for phase II trials without treating too many 
patients at suboptimal doses (  Table 2  ). Some of the challenges 
presented by model-based designs include the need for biostatisti-
cal expertise and available software on site to perform model fitting 
in real time, as well as an expedited collection of data from each 
cohort of patients to fit the model. As such, implementation of 
these designs may not be straightforward. In addition, the model 
may fail to reach the recommended dose for phase II trials if the 
prior distributions for the parameters of the dose  –  toxicity curve 
are inadequate, or conversely, if the prior assumptions are over-
bearing (  64  ). Finally, inclusion of one patient per dose level may 
accelerate the dose escalation, but may also deprive the investiga-
tors of data on interpatient pharmacokinetic variability, although 
this limitation can be easily dealt with by expanding the cohort size 
if such data are needed.     
    Designs for Trials of Combinations of 
Agents 
  Many phase I studies are designed to investigate combinations of 
two or more agents. The combination of two or more agents in the 
clinic should be based on a strong scientific rationale rather than 
simple empiricism. Unfortunately, preclinical models that accu-
rately predict synergism or even additivity are not well character-
ized, and existing preclinical models often focus on the antitumor 
effects of drug combinations while ignoring their potential for 
creating severe toxicities. Determining the recommended dose for 
phase II trials of agents to be administered in combination may 
appear easier than that for single agents, given that the recom-
mended dose for phase II trials and the toxicity of each drug are 
already known. For this reason, phase I combination trials usually 
explore only a limited number of dose levels. Korn and Simon (  65  ) 
developed a graphical method to define the MTDs of drugs to be 
used in combination that relies on the organ-specific toxicities of 
the drugs when given as single agents. However, this method was 
developed using cytotoxic drugs, which have a high likelihood of 
overlapping toxicities (in particular hematologic toxicities). By 
contrast, when drugs to be administered in combination have dif-
ferent mechanisms of action or nonoverlapping toxicities, the 
recommended dose for phase II trials for the drug combination is 
usually expected to be near the recommended dose for phase II 
trials of each drug given as a single agent. However, the biochemi-
cal and biological effects of the combination may be quite complex, 
and the dose  –  toxicity relationship may depend largely on unknown 
pharmacokinetic and/or pharmacodynamic interactions between 
the agents, which could limit the administration of all drugs at 
their recommended dose for phase II trials as single agents. In this 
case, it remains a challenge to determine which drugs should be 
administered at the full recommended dose for phase II trials and 
how to proceed with the dose escalation. 
  When a rule-based design is used for phase I trials of drug 
combinations, the dose levels must be chosen carefully so that the 
dose of each drug (or at least the ones felt to be most relevant) can 
be increased as close as possible to MTD. The choice of the dose 
levels to be tested may be based on several factors including pre-
clinical data, the current standard treatments in tumor types for 
which the combination is intended, the expected control arm if the 
combination under evaluation is planned to       be benchmarked in 
subsequent randomized trials, and/or sheer empiricism. Several 
strategies for dose escalation in phase I trials of two drugs are 
illustrated in   Figure 3  : 1) alternate escalation of the agents in the 
series of dose levels; 2) simultaneous escalation of both agents; 
3) escalation of one agent to the recommended dose for phase II 
trials while holding the other agent at a ﬁ  xed (generally high) dose; 
and 4) escalation of one agent to the recommended dose for phase 
II trials while holding the other agent at a low dose. In this latter 
case, the dose of the ﬁ  rst agent is then reduced by one or two dose 
levels while the dose of the other agent is escalated to the recom-
mended dose for phase II trials.         
  In the above-mentioned rule-based strategies, although the 
dose escalation is preset, uncertainty may remain at trial comple-
tion about the optimal drug combination that yields the best thera-
peutic index (  Table 1  ). Several Bayesian model  –  based designs 
speciﬁ  c for combination trials have been developed in an attempt 
to minimize this uncertainty. These designs do not require any 
prior assumptions about the best dose combination, and they aim 
to guide the dose escalation of the agents based on all toxicities 
observed (  63  ,  66    –    69  ). In these methods, the dose  –  toxicity probabil-
ity curves are updated after each cohort of patients for all agents by 
using all available toxicity data so that the subsequent cohort of 
patients may be assigned to the most appropriate dose combina-
tion. The ultimate goal is to determine the most active drug com-
bination among those also deemed to be safe. Some investigators 
have proposed methods for drug combination studies that use both 
toxicity and efﬁ   cacy as endpoints (  63  ,  67  ). For example, in the 
design proposed by Yin et al. (  63  ), patients are randomly assigned 
to one of several combinations that are selected by a statistical 
model to determine the most effective and least toxic combination. 
These methods, which incorporate both toxicity and efﬁ  cacy as 
endpoints  ,   may determine several MTDs, and the investigator may 
then choose the one with the best therapeutic index as the recom-
mended dose for phase II trials. 
  Pharmacokinetic analyses may provide information about 
interactions between anticancer drugs administered in combina-
tion. To learn about potential drug interactions, one may initiate 
treatment with a run-in period by administering only one drug, 
followed by concurrent dosing of other drugs. This strategy would 
allow one to compare within the same patient the pharmacokinetic 
proﬁ  le of the ﬁ  rst drug given alone with that obtained in the pres-
ence of the other drugs. Alternatively, comparisons can be made 
with historical published pharmacokinetic data of the drugs, with 
the limitations of heterogeneity that may exist between different 
patient populations and variations in assay sensitivities. 
  Von Hoff et al. (  70  ) have suggested a practical approach to 
conduct simultaneous independent parallel phase I combination 
studies that pair different chemotherapeutic agent or agents with a 
new drug, once the recommended dose of the new drug for phase 
II trials is known. This approach may expedite the accrual of 
patients because patients referred for a phase I trial may be eligible 
for more than one of the proposed combined regimens, if given the 
options. 
  Overall, the choice of the dose escalation scheme for drug com-
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trials. The recommended dosages and schedules can have a critical 
role in the success or failure of a combination regimen during its 
subsequent clinical development.   
    Designs for Trials of Molecularly Targeted 
Agents 
  In phase I cancer clinical trials that involve cytotoxic agents, the 
conventional primary endpoint has been toxicity, which, with effi-
cacy, is assumed to increase with the drug dose. Molecularly tar-
geted agents modulate specific aberrant pathways in cancer cells 
while sparing normal tissues, such that the toxicity and efficacy of 
these novel agents may not be dose dependent. Alternative end-
points besides toxicity have been proposed for phase I trials that 
evaluate molecularly targeted agents, including target inhibition in 
tumors or surrogate tissues and/or detection of biologically rele-
vant pharmacokinetic levels (  1    –    4  ). The assessment of target inhibi-
tion may be one of the most challenging aspects of clinical trial 
designs for several reasons (  71  ). First, tumor tissue or a valid sur-
rogate tissue must be readily available and easily accessible. 
Second, there must be a reliable assay for measuring the effect of 
the drug on the target. Third, the optimal extent of target inhibi-
tion (ie, inhibition that yields a meaningful clinical benefit) must 
be known      . Because these three conditions are rarely all met, a 
recommended dose for phase II trials that is established based 
solely on the measurement of target inhibition in a phase I trial 
may be suboptimal. Pharmacokinetic endpoints, such as the attain-
ment of plasma drug concentrations that were shown to correlate 
with biological activity in preclinical studies, may enable dose 
selection of some molecularly targeted agents in the phase I 
  setting. However, these endpoints are appropriate only if suffi-
cient preclinical data exist that demonstrate a convincing 
  pharmacokinetic  –  pharmacodynamic relationship. 
  In a limited number of reported clinical trials of molecularly 
targeted agents that fulﬁ  lled the above-mentioned conditions, spe-
ciﬁ  c designs were developed to deﬁ  ne the recommended dose for 
phase II trials (  72    –    75  ). For example, in a phase I trial of patients 
undergoing craniotomy for malignant glioma, Friedman et al. (  72  ) 
evaluated the safety and biological activity of administering 
O6-benzylguanine to inhibit the DNA repair protein O6-
alkylguanine-DNA alkyltransferase (AGT). The trial design stipu-
lated that up to 13 patients could be accrued at a dose level and that 
dose escalation would stop if the biological endpoint of AGT inhibi-
tion in resected tumor was met in at least 11 of the 13 patients. In 
addition, Hunsberger et al. (  73  ) proposed a design similar to that 
described by Friedman et al. except that it prespeciﬁ  es the desired 
proportion of patients who will display a biological response at a 
given dose level, as well as the minimal threshold for biological 
response. Other proposals for phase I trial designs speciﬁ  c  for 
molecularly targeted agents that have been described in the statisti-
cal literature await practical evaluations. For example, Mandrekar 
et al. (  74  ) developed a Bayesian-based method based on an extension 
of TriCRM that incorporates toxicity and a biological endpoint for 
molecularly targeted agent combinations. Polley and Cheung (  75  ) 
proposed a two-stage design for identifying the optimal biological 
dose that uses stepwise tests with a futility interim analysis. 
  To our knowledge, no speciﬁ  c clinical trial designs have been 
formulated to date for molecularly targeted agents that do not 
        Figure 3    .       Strategies for dose escalation in phase I 
trials testing combinations of two drugs.   White 
bars   represent drug 1,   gray bars   represent drug 
2.   A  ) Alternate dose escalation.   B  ) Simultaneous 
dose escalation.   C  ) Single-agent dose escalation. 
  D  ) Compromised dose escalation with only one 
of the two agents achieving full dose escalation. 
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have a proven relevant target and a validated method for mea-
suring target inhibition. The Task Force on Methodology for 
the Development of Innovative Cancer Therapies, which 
recently published its recommendations on phase I studies of 
targeted anticancer therapy (  76  ), has not provided guidance 
on dose escalation methods speciﬁ   c for molecularly targeted 
compounds.  
    Dose Escalation Methods Used in Recent 
Clinical Practice 
  Despite the abundance of new dose escalation methods that have 
been published in the clinical and statistical literature, the applica-
tion of these methods in practice has been limited. Rogatko et al. (  5  ) 
found that only 1.6% of 1235 phase I cancer trials published between 
1991 and 2006 used Bayesian adaptive designs such as the modified 
continual reassessment method or EWOC. To provide an update on 
dose escalation methods that have been used since that time period, 
we searched the SCOPUS       database for all phase I cancer trials that 
were published between January 1, 2007, and December 1, 2008, 
by using the following search algorithm: TITLE(((phase i) OR 
(phase 1) OR (phase one)) AND ((study) OR (studies) OR (trial) OR 
(trials)) AND ((cancer) OR (malignancies) OR (carcinoma) OR 
(carcinomas)) AND NOT ((phase ii) OR (phase i/ii) OR (phase 2) 
OR (phase iii) OR (phase ii/iii) OR (phase 3))) AND PUBYEAR 
AFT 2006 AND (LIMIT-TO(DOCTYPE, “ar”) OR LIMIT-
TO(DOCTYPE, “ip”) OR LIMIT-TO(DOCTYPE, “cp”)) AND 
(EXCLUDE(SUBJAREA, “PHYS”) OR EXCLUDE(SUBJAREA, 
“MATH”) OR EXCLUDE(SUBJAREA, “ENGI”)) AND (LIMIT-
TO(LANGUAGE, “English”)). 
  This search yielded 246 articles, of which 208 reported ﬁ  nd-
ings of a phase I trial (  Figure 4  ). We excluded 27 trials because 
no dose escalation was planned in the study (n = 12 trials) or 
because the full article was not accessible to determine the dose 
escalation method (n = 15 trials). Of the remaining 181 trials, 
175 (96.7%) used a traditional 3+3 design or variation and 6 
(3.3%) used model-based designs. Among the 175 trials using a 
rule-based design, 167 used the traditional 3+3 design, one 
applied the 3+3 design but with intrapatient dose escalation, 
and the remaining seven trials used one accelerated titration 
design. However, none of the trials with an accelerated titration 
design reported model ﬁ   tting for determining the recom-
mended dose for phase II trials. Although the use of model-
based designs was still very limited, this proportion has doubled 
compared with the 1991  –  2006 period (  5  ), suggesting a trend 
toward a greater use of modern dose escalation methods. 
Among the 181 phase I trials reviewed, 32 involved molecularly 
targeted agents that were administered as single agents. Among 
these 32 trials, toxicity remained the most common reason for 
stopping dose escalation (63%); 13% were stopped on the basis 
of pharmacokinetic data before MTD was reached. These per-
centages are similar to those reported by Parulekar and 
Eisenhauer (60% and 13%, respectively) in their review of 
phase I trials involving molecularly targeted agents adminis-
tered as monotherapy that were published through March 2003 
(  2  ). Toxicity remains the most widely used primary endpoint in 
phase I cancer clinical trials.           
    Discussion 
  A retrospective analysis of oncology phase I trials published 
between 1991 and 2002 has revealed that most of the objective 
tumor responses in phase I trials occurred when study drugs (pri-
marily cytotoxic agents) were administered at 80% or more of 
their subsequent recommended dose for phase II trials (  77  ). 
Evaluation of new dose escalation methods is needed to maximize 
the proportion of patients being treated at or near the recom-
mended dose for phase II trials. Statistical simulations have dem-
onstrated that new trials designs are frequently more efficient than 
the traditional 3+3 design in that they optimize the proportion of 
patients who are treated at or near the recommended dose for 
phase II trials and/or reduce the duration of time required to com-
plete accrual. However, despite these putative advantages, most of 
the new methods have rarely been implemented in clinical practice 
(  5  ,  78  ,  79  ). Our review also found that the modeling features in the 
accelerated titration design are rarely used in clinical practice. 
Some investigators have retrospectively assessed the efficiency, 
safety, and efficacy (eg, response rate) of different dose escalation 
methods used in phase I trials (  80    –    83  ). Although these reports are 
quite heterogeneous in terms of time periods of the studies 
included, the nature of the studies (monotherapy trials or combi-
nation trials), and the type of anticancer agents (cytotoxic agents or 
molecularly targeted agents), they suggest that some of the newer 
methods, such as the modified continual reassessment method, 
expose fewer patients to subtherapeutic doses than the traditional 
3+3 design but do not result in shorter trial durations (  80  ,  81  ). This 
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latter point may reflect the fact that many other factors besides the 
speed of the dose escalation can slow the course of a trial, including 
amendment requirements, sluggish patient accrual, competing tri-
als, and unexpected toxicities. Whether the use of new dose escala-
tion methods results in improved safety and/or efficacy in phase I 
trials remains unclear (  82  ,  83  ). Whereas one review (  82  ) claimed 
that the traditional 3+3 design is the safest in terms of grade 3 or 4 
nonhematologic and grade 4 hematologic toxicities and had effi-
cacy that is similar to that of more aggressive dose escalation 
methods, another review (  83  ) found an increased response rate but 
no increased risk of toxicity when intrapatient dose escalation was 
allowed. Of note, the overall response rates reported by these two 
reviews were similar to those observed in other reviews of phase I 
trials (ie, 2%  –  11%) (  79  ,  84    –    86  ). Furthermore, it may not be appro-
priate to compare response rates across phase I studies because 
efficacy is not the primary objective, and response assessment in 
these trials is complicated by the heterogeneity of the patient 
population and variability in the biological activities of the agents 
being evaluated. It is yet to be determined by prospective clinical 
trials whether the new dose escalation methods are as safe as the 
traditional 3+3 design and whether they provide greater efficacy. 
  Clinicians may ﬁ  nd it more informative to know appropriate 
settings in which a speciﬁ  c dose escalation method would be more 
efﬁ  cient than the traditional 3+3 design while offering a similar 
degree of safety than to be given generalized recommendations on 
the application of phase I dose escalation methods. Preclinical 
data, including toxicology and pharmacology data, existing knowl-
edge about the inhibition of the putative pathway and the resulting 
on-target and off-target effects, and available information about 
the drug or similar classes of drugs, should help formulate the trial 
design decision and may also provide valuable guidance on how 
best to proceed with a ﬁ  rst-in-human phase I cancer clinical trial. 
If the preclinical data indicate a wide therapeutic window and little 
expected toxicity in human subjects, it is very reasonable to apply 
an aggressive dose titration (eg, by using an accelerated titration 
design or Bayesian-based methods), at least at the beginning of the 
phase I trial. However, if the preclinical data were less certain 
about how human subjects will tolerate the drug or predict a very 
narrow therapeutic window, then it would be prudent to choose a 
more conservative dose escalation scheme. For trials of drug com-
binations, the most challenging issue is likely to be the choice of 
the dose escalation scheme. The traditional 3+3 design is presum-
ably a reasonable design if an expected optimal dose combination 
is speciﬁ  ed before starting the trial. On the contrary, if the optimal 
dose combination is not prespeciﬁ  ed, Bayesian model  –  based meth-
ods may help to determine the safest and most effective drug 
combination. Finally, speciﬁ  c dose escalation methods that incor-
porate time-to-event endpoints, such as the TITE-CRM, should 
be considered for drugs that are expected to produce delayed or 
cumulative toxicities. 
  It is unclear if the new dose escalation designs that have been 
proposed in the era of cytotoxic chemotherapy can be readily 
applied to molecularly targeted agents, or if different designs speciﬁ  c 
for such agents are needed (  1  ). The main properties of molecularly 
targeted agents that distinguish them from cytotoxic agents include 
their allegedly superior therapeutic indices and the potential for 
identifying predictive biomarkers that correlate with clinical out-
come and pharmacodynamic biomarkers that can conﬁ  rm molecular 
mechanisms of activity. Whether the proposed differences between 
molecularly targeted agents and cytotoxic chemotherapy justify a 
need for distinctive phase I trial designs is debatable. In practice, 
however, toxicity has remained the primary endpoint of the vast 
majority of published phase I trials, as demonstrated by others previ-
ously (  2  ) and by our own update in this review. Furthermore, as 
many as half of the molecularly targeted agents that were eventually 
approved by the US FDA underwent dose escalation in phase I trials 
until toxicity was observed (  Table 3  ); the exceptions were monoclo-
nal antibodies, for which dose escalations were stopped on the basis 
of favorable pharmacokinetic data, and agents such as imatinib, 
which demonstrated dramatic efﬁ  cacy in the disease under investiga-
tion as well as a favorable pharmacokinetic proﬁ  le before any dose-
limiting toxicity was encountered. The identiﬁ  cation of an optimal 
biological dose in phase I trials of molecularly targeted agents based 
on tissue-based biomarkers or plasma drug concentrations is chal-
lenging (  87  ). The evaluation of predictive and/or pharmacodynamic 
biomarkers in phase I trials remains highly exploratory because of 
their small sample size, the heterogeneity of the patient population, 
and the lack of a control group. Only randomized controlled trials 
can validate relationships between these biomarkers and clinical 
outcome. Therefore, unless one is conﬁ  dent of the validity of the 
method of ascertaining biological activity of a new agent, toxicity 
should remain the most relevant reason to stop dose escalation in 
phase I trials (  3  ). 
  Phase I trials in which a molecularly targeted agent is matched 
precisely with a population of patients whose tumors are driven 
predominantly by the target of interest, as in the cases of imatinib 
in chronic myelogenous leukemia and trastuzumab in   HER2  -
ampliﬁ  ed breast cancer, are rare. The vast majority of phase I trials 
evaluate new agents for which target tumor types have not yet been 
identiﬁ  ed, and, as in phase I trials of cytotoxic compounds, toxicity 
is the primary endpoint and biomarker endpoints are only exam-
ined in exploratory analyses. Given these considerations, we pre-
sume that dose escalation methods developed in the era of 
cytotoxic agents are largely applicable to molecularly targeted 
agents. Continual efforts should be invested to evaluate the appro-
priateness of such applications and to explore new dose escalation 
methods that may better suit the properties of molecularly tar-
geted agents. Deriving the optimal (ie, efﬁ  cient and safe) dose 
escalation methods for anticancer therapies continues to be a chal-
lenge. However, there are many new designs proposed in recent 
literature. The use and evaluation of these new methods should be 
encouraged so that further improvements can be made to expedite 
the drug development process.   
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